36
Participants
Start Date
July 27, 2020
Primary Completion Date
December 31, 2020
Study Completion Date
December 31, 2020
VNRX-5024
"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
Placebo for VNRX-5024
"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
PRA Health Sciences - Early Development Services, Groningen
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Venatorx Pharmaceuticals, Inc.
INDUSTRY